Niceritrol Inhibitor

Niceritrol is an ester of nicotinic acid. It also lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.

Owada A, Suda S, Hata T. Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. Am J Med. 2003 Apr 1;114(5):347-53. PubMed PMID: 12714122.
Yamamoto K, Fukushima N, Ozaki I, Setoguchi Y, Yanagita T, Sakai T. New combined therapy of niceritrol and probucol on heterozygous familial hypercholesterolemia. Artery. 1991;18(3):133-49. PubMed PMID: 2069518.
Kuboyama N, Watanabe Y, Yamaguchi M, Sato K, Suzuki T, Akiba T. Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant. 1999 Mar;14(3):610-4. PubMed PMID: 10193807.
Nagakawa Y, Orimo H, Harasawa M. The anti-platelet effect of niceritrol in patients with arteriosclerosis and the relationship of the lipid-lowering effect to the anti-platelet effect. Thromb Res. 1985 Nov 15;40(4):543-53. PubMed PMID: 4082125.

Small volumes of Niceritrol, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5756245 is an inhibitor targeting Niceritrol.